https://www.selleckchem.com/products/mrtx1719.html
3 months (0.6-23.6), median PFS was 3.5 months (95%CI 2.4-3.8) and median OS 7.9 months (95%CI 5.1-10.2). PFS was significantly longer in patients with grade ≥ 2 cutaneous toxicities vs patients with grade 0-1 toxicities (HR = 0.55, 95%CI 0.33-0.92, P = .02. Expression of EGFR and HER2 was correlated with PFS and OS in multivariate analysis; HER2 expression was correlated with the tumor response. Main severe toxicities were neutropenia (32%), cutaneous rash (37%) and thrombosis/embolisms (35.5%). This triplet combination is effective
Like
Comment
Share
